ALSO READCadila Healthcare gains after partnering with Takeda Cadila Healthcare gains after tie-up with Turkish firm Cadila Healthcare jumps after Moraiya facility receives EIR Cadila Healthcare jumps after USFDA approval for anti-diabetic drug Cadila Healthcare inches up after acquiring two ANDAs from Teva
Meanwhile, the BSE Sensex was up 132.61 points, or 0.50%, to 26,482.78.
On BSE, so far 24,000 shares were traded in the counter, compared with average daily volume of 70,800 shares in the past one quarter. The stock hit a high of Rs 414.60 and a low of Rs 399.10 so far during the day. The stock hit a 52-week high of Rs 429.45 on 1 November 2016. The stock hit a 52-week low of Rs 295.50 on 18 January 2016. The stock had outperformed the market over the past 30 days till 28 November 2016, falling 1.86% compared with the 5.66% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 6.50% as against Sensex's 7.03% decline.
The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.
Shares of Cadila Healthcare rose 12.51% in five trading sessions to settle at Rs 411 yesterday, 28 November 2016, from its close of Rs 365.30 on 21 November 2016.
Cadila Healthcare's consolidated net profit fell 28.93% to Rs 337.60 crore on 3.08% increase in net sales to Rs 2336.30 crore in Q2 September 2016 over Q2 September 2015.
Cadila Healthcare is a global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)